Is there a light at the end of the tunnel?
News & Analysis: Idera Pharmaceuticals
Investors are cheering the orphan drug specialist's decision to raise a nice chunk of capital via a public offering.
From a scuttled merger to tariff troubles, see why shares of these three companies fell hard today.
Shares plunge after its proposed merger is called off. Here's what investors need to know.
The company released preliminary data from an important phase 1/2 study.
Find out which company announced a merger.
Is this a merger out of weakness and necessity? Wall Street might think so.
Investors may want to put Idera Pharmaceuticals, Yamana Gold, and Ekso Bionics on their watchlists.
New phase 1/2 trial data show the biotech's drug candidate IMO-2125 is working.
It makes sense on paper, but is little more than wishful thinking in reality.